T-Cell Activation State Reshapes Asthma Genetics and Points to New Drug Targets

Asthma is one of the most common chronic immune-mediated diseases in the world, and decades of genome-wide association studies have made it abundantly clear that inherited DNA variation contributes substantially to who develops it. Yet converting those long lists of genetic risk locations into actual therapeutic targets has proven stubbornly difficult. A new study published in the Journal of Translational Medicine argues that part of the problem lies in a deceptively simple oversight: the immune cells most relevant to asthma do not sit still, and neither does their genetic wiring. Researchers led by Qiulin Yan and Jiaoli Luo of Changsha Hospital of Traditional Chinese Medicine, working with colleagues at Hunan University of Chinese Medicine, have shown that the genetic regulation of gene expression in CD4+ T cells shifts dramatically depending on the activation state of the cell, and that capturing those shifts reveals asthma drug targets that conventional approaches overlook.

The central tools of the study were expression quantitative trait loci, or eQTLs. An eQTL is a genetic variant that correlates with the expression level of a particular gene, effectively serving as a naturally occurring experiment in gene regulation. Most large-scale eQTL catalogs, however, are built from cells sampled at rest, in what researchers call a steady state. For immune cells, that is a biologically artificial situation. CD4+ T cells are the conductors of the adaptive immune response, and in asthma they orchestrate airway inflammation through specialized lineages such as Th2 cells, which drive the allergic responses characteristic of much of the disease burden, as well as Th17 and T follicular helper cells. When a naive CD4+ T cell encounters antigen and becomes activated, it reprograms its transcriptional landscape, its signaling networks, and its epigenetic architecture. A variant that strongly controls a gene in a resting cell may be functionally silent in an activated effector cell, and vice versa.

To test whether this matters for asthma genetics, the team integrated activation-resolved eQTL data covering multiple stages of CD4+ T-cell activation with two independent statistical frameworks. The first was two-sample Mendelian randomization, a technique that uses genetic variants as instrumental variables to ask whether altered expression of a gene causally influences a disease outcome, rather than merely co-occurring with it. The second was genetic colocalization, which tests whether an association signal for gene expression and an association signal for disease risk in the same genomic region are driven by the same causal variant. Together, these methods filter the noisy universe of statistical correlations down to a smaller set of genes whose regulation is plausibly and specifically linked to asthma through shared genetic mechanisms. The asthma evidence came from genome-wide association study summary statistics, allowing the entire analysis to run on aggregated, de-identified data without any new human sampling.

The scale of the screen was substantial. Across 7,295 genes, the researchers performed 34,266 Mendelian randomization tests spanning the different activation stages. Of these, 316 genes showed significant genetic support for a causal relationship with asthma risk, and 278 of those were further backed by colocalization evidence, meaning the same variant could plausibly explain both the altered gene expression and the altered disease risk. The striking result was where these signals appeared. Genetically supported associations were far more frequent at intermediate and late stages of T-cell activation, and the majority were confined to a single activation state. A static, resting-cell eQTL catalog simply could not see most of them.

The contrast with conventional resources was quantified directly. The researchers benchmarked their activation-resolved approach against four widely used static eQTL datasets, drawn from the OneK1K, DICE, GTEx, and eQTLGen consortia. Under the study’s criteria, 163 of the 278 colocalization-supported genes, or 58.6 percent, emerged only from the activation-resolved analysis. That is not a marginal improvement; it means the majority of genetically credible asthma regulatory signals detectable in activated T cells were invisible to the standard reference maps that much of human genetics relies upon. The pattern was not uniform across T-cell biology either. The prioritized genes were enriched in activated and effector CD4+ T-cell subsets, with particularly strong representation in the CD4_STIM activated population and in Th2, T follicular helper, and Th17 lineages, each of which has well-established roles in asthmatic airway inflammation.

The team also examined how regulatory effects behaved across activation stages and found recurring temporal profiles. Some genes showed sustained regulatory influence across all stages, while others displayed what the authors call direction-switch patterns, in which the same genetic variant pushes gene expression up in one activation state and down in another. This heterogeneity has real implications. It suggests that the genetic architecture of asthma risk is not a fixed property of a gene but a dynamic property of a gene within a cellular context, and that collapsing all states into a single average can both dilute genuine signals and obscure effects that reverse direction. The researchers were careful, however, to frame these findings appropriately: the patterns reflect differences in genetically supported associations across activation states, not direct proof that causal effects change over time in living patients.

Independent validation strengthened the case. Using summary statistics from the Global Biobank Meta-analysis Initiative, the team re-tested 787 primary Mendelian randomization-supported cell-state and gene pairs. A total of 477 pairs, 60.6 percent, were replicated in the external dataset, and of the replicated pairs 97.1 percent showed effect directions consistent with the original analysis. That degree of directional concordance is reassuring, because replication with flipped effect directions would have suggested unstable or spurious findings. Instead, it indicates that activation-resolved eQTL signals linked to asthma are robust across independent cohorts of European ancestry.

The translational payoff of the study is a structured shortlist of 47 candidate genes for drug development. Priority was assigned by combining the genetic evidence with existing drug-target databases and clinical evidence. Notably, seven of the candidates already have links to asthma-related clinical trials, providing an immediate sanity check on the pipeline, while others carry potential relevance for drug repurposing, meaning existing medicines aimed at those targets could be evaluated in asthma with a head start on safety data. Genes supported both by human genetics and by existing pharmacology are widely regarded as the highest-yield starting points for drug discovery, because human genetic validation substantially raises the probability that modulating a target will produce clinical benefit.

The study also probed why activation-specific signals exist at all. The analysis showed that greater CD4+ T-cell specificity of a gene was associated with increased odds that its regulatory signal was restricted to a particular activation stage, with an odds ratio of 1.18 per unit increase, a 95 percent confidence interval of 1.11 to 1.25, and a P value of 1.4 times ten to the minus seventh, surviving correction for multiple testing. In plain terms, genes whose expression is highly specialized to CD4+ T cells are more likely to show activation-context-dependent regulation, which fits the biology of immune cells whose identity is defined by state-specific transcriptional programs.

Important caveats accompany the findings. The eQTL and GWAS resources underlying the work were derived predominantly from individuals of European ancestry, so generalizing the prioritized targets to other populations will require additional datasets. Mendelian randomization and colocalization, powerful as they are, operate on summary statistics and indirect genetic instruments, and their conclusions are only as good as the assumptions underlying those instruments. Even so, the broader message is likely to reshape how immunogeneticists approach complex disease. The study demonstrates that the cellular state in which gene regulation is measured is not a technical detail but a first-order determinant of what genetic association studies can find. For asthma, a disease whose immunology is defined by activated effector T cells, resting-state reference maps have been effectively photographing the wrong moment. Activation-resolved eQTL atlases, the authors argue, should be treated as complementary and essential resources, and the 47-gene shortlist they produce offers drug developers a genetically grounded place to look next.

Subject of Research: Activation-resolved eQTL and Mendelian randomization analysis of CD4+ T-cell genetic regulation in asthma

Article Title: Activation-dependent genetic regulation in CD4⁺ T cells prioritizes druggable targets for asthma

Article References: Yan, Q., Liu, D., Yan, L., Wang, J., Li, L., Tan, L., Li, D., Nie, J., & Luo, J. (2026). Activation-dependent genetic regulation in CD4⁺ T cells prioritizes druggable targets for asthma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09033-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09033-w

Keywords: asthma, CD4+ T cells, eQTL, Mendelian randomization, colocalization, GWAS, drug target prioritization, gene regulation, immunogenetics, T-helper cells, translational medicine, Activation-dependent